Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Corin Badiu x
Clear All Modify Search
Rodrigo Moreno-Reyes R Moreno-Reyes, Department of Nuclear Medicine, Université Libre de Bruxelles, Bruxelles, 1050, Belgium

Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Close
,
Ulla Feldt-Rasmussen U Feldt-Rasmussen, Department of Endocrinology and Metabolism, University of Copenhagen, Kobenhavn, 1165, Denmark

Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Close
,
Agnieszka Piekiełko-Witkowska A Piekiełko-Witkowska, Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, 01-813, Poland

Search for other papers by Agnieszka Piekiełko-Witkowska in
Google Scholar
PubMed
Close
,
Adriana Gaspar da Rocha A Gaspar da Rocha, Public Health Unit, University of Porto Institute of Molecular Pathology and Immunology, Porto, 4200-465, Portugal

Search for other papers by Adriana Gaspar da Rocha in
Google Scholar
PubMed
Close
,
Corin Badiu C Badiu, National Institute of Endocrinology "C Davila" University of Medicine and Pharmacy, Bucharest, Romania

Search for other papers by Corin Badiu in
Google Scholar
PubMed
Close
,
Josef Koehrle J Koehrle, Institut für Experimentelle Endokrinologie, Berlin, Germany

Search for other papers by Josef Koehrle in
Google Scholar
PubMed
Close
, and
Leonidas Duntas L Duntas, Metabolism and Diabetes National Kapodistrian University of Athens, Athens, Greece

Search for other papers by Leonidas Duntas in
Google Scholar
PubMed
Close

Abstract

In 2022, the European Chemicals Agency (ECHA) made a statement concluding that iodine is an endocrine disruptor (ED). "We stress the fact that the ECHA opinion ECHA/BPC/357/2022 is based on their misguidedly zooming in on exclusively the biocidal products (e.g., hand disinfectants, disinfection of animals’ teats/udder, embalming fluids before cremation, etc.) that contain molecular iodine (I2), entirely neglecting [see the 2013 ECHA Regulation (EU) n°528/2012 describing iodine as being of “great importance for human health”. Clearly, the current sweeping and erroneous classification of “iodine” as an endocrine disruptor is ill-advised. We moreover call upon the scientific and medical community at large to use the accurate scientific nomenclature, i.e., iodide or iodate instead of “iodine” when referring to iodized salts and food prepared there with. Drugs, diagnostic agents, and synthetic chemicals containing the element iodine in the form of covalent bonds must be correctly labelled ‘’iodinated’’, if possible, using each time their distinctive and accurate chemical or pharmacological name.

Open access
Rodrigo Moreno-Reyes Department of Nuclear Medicine, Hospital Erasme, Université Libre de Bruxelles, Brussels, Belgium

Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Close
,
Ulla Feldt-Rasmussen Department of Endocrinology and Metabolism, University Hospital Rigshospitalet, and Faculty of Ηealth and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Close
,
Agnieszka Piekiełko-Witkowska Centre of Postgraduate Medical Education, Centre of Translational Research, Department of Biochemistry and Molecular Biology, Warsaw, Poland: Basic Lead of the European Society of Endocrinology Focus Area on Thyroid

Search for other papers by Agnieszka Piekiełko-Witkowska in
Google Scholar
PubMed
Close
,
Adriana Gaspar da Rocha Public Health Unit, ULS Baixo Mondego, Figueira da Foz, Portugal Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Health Investigation and Innovation Institute (i3S), University of Porto, Porto, Portugal

Search for other papers by Adriana Gaspar da Rocha in
Google Scholar
PubMed
Close
,
Corin Badiu National Institute of Endocrinology "C. Davila" University of Medicine and Pharmacy, Bucharest, Romania

Search for other papers by Corin Badiu in
Google Scholar
PubMed
Close
,
Josef Köhrle Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Experimentelle Endokrinologie, Berlin, Germany: Co-Lead of the European Society of Endocrinology Focus Area on Environmental Endocrinology

Search for other papers by Josef Köhrle in
Google Scholar
PubMed
Close
, and
Leonidas Duntas Evgenideion Hospital, Unit of Endocrinology, Metabolism and Diabetes, National Kapodistrian University of Athens, Athens, Greece

Search for other papers by Leonidas Duntas in
Google Scholar
PubMed
Close

Graphical abstract

Abstract

In 2022, the European Chemicals Agency (ECHA) made a statement concluding that iodine is an endocrine disruptor (ED). We stress the fact that the ECHA opinion ECHA/BPC/357/2022 is based on their misguidedly zooming in on exclusively the biocidal products (e.g. hand disinfectants, disinfection of animals’ teats/udder, embalming fluids before cremation) that contain molecular iodine (I2), entirely neglecting the 2013 ECHA Regulation (EU) no. 528/2012 describing iodine as being of ‘great importance for human health’. Clearly, the current sweeping and erroneous classification of ‘iodine’ as an endocrine disruptor is ill-advised. We moreover call upon the scientific and medical community at large to use the accurate scientific nomenclature, i.e. iodide or iodate instead of ‘iodine’ when referring to iodized salts and food prepared there with. Drugs, diagnostic agents, and synthetic chemicals containing the element iodine in the form of covalent bonds must be correctly labeled ‘iodinated’, if possible, using each time their distinctive and accurate chemical or pharmacological name.

Open access